About the project

The National Hybrid Closed Loop Adoption and Type 1 Diabetes Outpatient Transformation Programme is a nationally coordinated initiative to increase access to Hybrid Closed Loop (HCL) technology for eligible people living with type 1 diabetes across England while transforming how outpatient diabetes care is delivered. The programme is led by the Health Innovation Network (South London) in partnership with NHS England, on behalf of the Health Innovation Network.  

Hybrid Closed Loop technology combines an insulin pump, continuous glucose monitoring sensor and an algorithm that automatically adjusts insulin delivery in response to glucose levels. The programme supports NHS systems to expand access to this life-changing technology while using HCL adoption as a catalyst for wider outpatient transformation, helping shift care from hospital to community settings, from reactive treatment to prevention, and from analogue to digitally enabled models of care.  

Health Innovation Networks work alongside NHS regional diabetes teams, Integrated Care Boards, provider organisations and diabetes services to support implementation that reflects local priorities and service structures.

Project ambitions

National ambitions 

• Increase access to Hybrid Closed Loop technology for eligible people living with type 1 diabetes across England.
• Support NHS systems to maximise use of the current reimbursement model and plan for sustainable long-term delivery.
• Transform outpatient diabetes services through digitally enabled, preventative and community-based models of care.
• Reduce unwarranted variation in access and uptake across different regions and population groups.
• Improve reporting, data collection and evidence generation through the National Diabetes Audit (NDA).  

 Health Innovation Network ambitions 

• Support pathway mapping and redesign of diabetes services for HCL-enabled care.   
• Develop workforce capacity and capability through training, modelling and sustainable workforce planning.  
• Support business case development and investment decisions.  
• Share learning, best practice and innovation opportunities across regions.  
• Help address health inequalities and ensure equitable adoption of HCL technology. 

Key facts

• There were approximately 284,010 people living with type 1 diabetes in England in 2024-25.
• Hybrid Closed Loop technology can significantly improve glucose control and support people to manage their diabetes more effectively.
• An NHS pilot reported average HbA1c reductions from 9.3% to 7.7% following HCL use.

Additional resources

National Hybrid Closed Loop Adoption and Type 1 Diabetes Outpatient Transformation Programme landing page.  

Hybrid Closed Loop Adoption and Type 1 Diabetes Outpatient Transformation Implementation Toolkit.  

Hybrid Closed Loop Workforce Capacity Modelling Tool. 

National Diabetes audit reporting dashboard.  

Programme case studies, webinars, podcasts and thought leadership resources as they are developed will be shared here. 

1. Blog: Why Hybrid Closed Loop technology could transform type 1 diabetes care across England 

1. Blog: Diabetes UK 2026 and what it means for our national Hybrid Closed Loop programme 

1. NHS England: Hybrid Closed Loop technology 

1. NHS England: Hybrid Closed Loop Technologies 5-Year Implementation Strategy 

1. Diabetes UK: NHS England rolls out artificial pancreas technology 

Find out more

National contact:

National HCL Programme Team, Health Innovation Network South London, t1nationalhclprogramme@nhs.net   

Health Innovation West Midlands contact: 

Baljit Marway, Project Manager, Baljit.Marway@healthinnovationwm.org